<- Go Home
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Market Cap
$5.2M
Volume
1.7M
Cash and Equivalents
$14.9M
EBITDA
-$121.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.38
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.34
Price / Earnings
-0.03
Price / Tangible Book Value
0.34
Enterprise Value
-$8.6M
Enterprise Value / EBITDA
0.08
Operating Income
-$127.2M
Return on Equity
185.31%
Return on Assets
-46.63
Cash and Short Term Investments
$14.9M
Debt
$1.1M
Equity
$15.1M
Revenue
N/A
Unlevered FCF
-$83.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium